nodes	percent_of_prediction	percent_of_DWPC	metapath
Ramipril—Hypersensitivity—Teniposide—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Ramipril—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Ramipril—Flushing—Carmustine—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Ramipril—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Ramipril—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Ramipril—Asthenia—Teniposide—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Ramipril—Malaise—Bleomycin—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Ramipril—Pruritus—Teniposide—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Ramipril—Arrhythmia—Carmustine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Ramipril—Leukopenia—Bleomycin—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Ramipril—Alopecia—Carmustine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Ramipril—Body temperature increased—Fludarabine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ramipril—Mental disorder—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Ramipril—Erythema—Carmustine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Ramipril—Malnutrition—Carmustine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Ramipril—Cough—Bleomycin—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Ramipril—Diarrhoea—Teniposide—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Ramipril—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Ramipril—Chest pain—Bleomycin—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Ramipril—Myalgia—Bleomycin—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Ramipril—Alopecia—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Ramipril—Discomfort—Bleomycin—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Ramipril—Mental disorder—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Ramipril—Urine output increased—Methotrexate—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Ramipril—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Ramipril—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Ramipril—Alopecia—Mitoxantrone—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Ramipril—Confusional state—Bleomycin—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Ramipril—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Ramipril—Tremor—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Ramipril—Oedema—Bleomycin—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Ramipril—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Ramipril—Erythema—Mitoxantrone—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Ramipril—Vomiting—Teniposide—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Ramipril—Agitation—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Ramipril—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Ramipril—Asthenia—Fludarabine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Ramipril—Rash—Teniposide—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Ramipril—Dermatitis—Teniposide—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Ramipril—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Ramipril—Headache—Teniposide—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Ramipril—Pruritus—Fludarabine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Ramipril—Leukopenia—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Ramipril—Anorexia—Bleomycin—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Ramipril—Agitation—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Ramipril—Polyuria—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Ramipril—Photosensitivity—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Ramipril—Hypotension—Bleomycin—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Ramipril—Diarrhoea—Fludarabine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Ramipril—Convulsion—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Ramipril—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Ramipril—Nausea—Teniposide—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Ramipril—Vertigo—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Ramipril—Hepatic failure—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Ramipril—Leukopenia—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Ramipril—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Ramipril—Chest pain—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Ramipril—Myalgia—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Ramipril—Anxiety—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Ramipril—Paraesthesia—Bleomycin—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Ramipril—Malaise—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Ramipril—Dyspnoea—Bleomycin—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Ramipril—Renal failure acute—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Ramipril—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Ramipril—Convulsion—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Ramipril—Confusional state—Carmustine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Ramipril—Oedema—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Ramipril—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Ramipril—Decreased appetite—Bleomycin—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Ramipril—Myalgia—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Ramipril—Cough—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Ramipril—Vomiting—Fludarabine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Ramipril—Convulsion—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Ramipril—Rash—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Ramipril—Dermatitis—Fludarabine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Ramipril—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Ramipril—Headache—Fludarabine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Ramipril—Tachycardia—Carmustine—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Ramipril—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Ramipril—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Ramipril—Chest pain—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Ramipril—Myalgia—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Ramipril—Anxiety—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Ramipril—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Ramipril—Discomfort—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Ramipril—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ramipril—Oedema—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ramipril—Anorexia—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Ramipril—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Ramipril—Confusional state—Mitoxantrone—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Ramipril—Nervous system disorder—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Ramipril—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Ramipril—Hypotension—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Ramipril—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Ramipril—Oedema—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Ramipril—Nausea—Fludarabine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Ramipril—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Ramipril—Shock—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ramipril—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ramipril—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ramipril—Urticaria—Bleomycin—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ramipril—Anorexia—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Ramipril—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Ramipril—Body temperature increased—Bleomycin—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Ramipril—Insomnia—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Ramipril—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Ramipril—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Ramipril—Paraesthesia—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Ramipril—Hypotension—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Ramipril—Dyspnoea—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Ramipril—Somnolence—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Ramipril—Anorexia—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Ramipril—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Ramipril—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Ramipril—Decreased appetite—Carmustine—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Ramipril—Hypotension—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Ramipril—Insomnia—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Ramipril—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Ramipril—Paraesthesia—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Ramipril—Constipation—Carmustine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Ramipril—Breast disorder—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Ramipril—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Ramipril—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Ramipril—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Ramipril—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Ramipril—Decreased appetite—Vincristine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Ramipril—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Ramipril—Somnolence—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Ramipril—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Ramipril—Feeling abnormal—Carmustine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Ramipril—Fatigue—Vincristine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Ramipril—Asthenia—Bleomycin—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Ramipril—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Ramipril—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Ramipril—Constipation—Vincristine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Ramipril—Asthma—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Ramipril—Pruritus—Bleomycin—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Ramipril—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ramipril—Eosinophilia—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Ramipril—Fatigue—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ramipril—Pancreatitis—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Ramipril—Constipation—Mitoxantrone—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Ramipril—Abdominal pain—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Ramipril—Body temperature increased—Carmustine—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Ramipril—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Ramipril—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Ramipril—Pancytopenia—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Ramipril—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Ramipril—Neutropenia—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ramipril—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ramipril—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Ramipril—Abdominal pain—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ramipril—Body temperature increased—Vincristine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ramipril—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Ramipril—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Ramipril—Urticaria—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ramipril—Hypersensitivity—Carmustine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Ramipril—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ramipril—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Ramipril—Vomiting—Bleomycin—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Ramipril—Rash—Bleomycin—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Ramipril—Dermatitis—Bleomycin—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Ramipril—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Ramipril—Asthenia—Carmustine—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Ramipril—Renal failure—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Ramipril—Stomatitis—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ramipril—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ramipril—Hypersensitivity—Vincristine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Ramipril—Sweating—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Ramipril—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ramipril—Epistaxis—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ramipril—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ramipril—Asthenia—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ramipril—Diarrhoea—Carmustine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Ramipril—Nausea—Bleomycin—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Ramipril—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Ramipril—Asthenia—Mitoxantrone—lymphatic system cancer	0.001	0.001	CcSEcCtD
Ramipril—Dizziness—Carmustine—lymphatic system cancer	0.000993	0.000993	CcSEcCtD
Ramipril—Diarrhoea—Vincristine—lymphatic system cancer	0.000981	0.000981	CcSEcCtD
Ramipril—Hepatitis—Methotrexate—lymphatic system cancer	0.000979	0.000979	CcSEcCtD
Ramipril—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000955	0.000955	CcSEcCtD
Ramipril—Vomiting—Carmustine—lymphatic system cancer	0.000955	0.000955	CcSEcCtD
Ramipril—Dizziness—Vincristine—lymphatic system cancer	0.000948	0.000948	CcSEcCtD
Ramipril—Rash—Carmustine—lymphatic system cancer	0.000947	0.000947	CcSEcCtD
Ramipril—Dermatitis—Carmustine—lymphatic system cancer	0.000946	0.000946	CcSEcCtD
Ramipril—Visual impairment—Methotrexate—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Ramipril—Headache—Carmustine—lymphatic system cancer	0.000941	0.000941	CcSEcCtD
Ramipril—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000926	0.000926	CcSEcCtD
Ramipril—Tinnitus—Methotrexate—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Ramipril—Vomiting—Vincristine—lymphatic system cancer	0.000911	0.000911	CcSEcCtD
Ramipril—Rash—Vincristine—lymphatic system cancer	0.000904	0.000904	CcSEcCtD
Ramipril—Dermatitis—Vincristine—lymphatic system cancer	0.000903	0.000903	CcSEcCtD
Ramipril—Headache—Vincristine—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Ramipril—Nausea—Carmustine—lymphatic system cancer	0.000892	0.000892	CcSEcCtD
Ramipril—Vomiting—Mitoxantrone—lymphatic system cancer	0.000888	0.000888	CcSEcCtD
Ramipril—Immune system disorder—Methotrexate—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Ramipril—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000882	0.000882	CcSEcCtD
Ramipril—Rash—Mitoxantrone—lymphatic system cancer	0.00088	0.00088	CcSEcCtD
Ramipril—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000879	0.000879	CcSEcCtD
Ramipril—Headache—Mitoxantrone—lymphatic system cancer	0.000875	0.000875	CcSEcCtD
Ramipril—Alopecia—Methotrexate—lymphatic system cancer	0.000865	0.000865	CcSEcCtD
Ramipril—Mental disorder—Methotrexate—lymphatic system cancer	0.000858	0.000858	CcSEcCtD
Ramipril—Erythema—Methotrexate—lymphatic system cancer	0.000852	0.000852	CcSEcCtD
Ramipril—Malnutrition—Methotrexate—lymphatic system cancer	0.000852	0.000852	CcSEcCtD
Ramipril—Nausea—Vincristine—lymphatic system cancer	0.000851	0.000851	CcSEcCtD
Ramipril—Dysgeusia—Methotrexate—lymphatic system cancer	0.000835	0.000835	CcSEcCtD
Ramipril—Nausea—Mitoxantrone—lymphatic system cancer	0.000829	0.000829	CcSEcCtD
Ramipril—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000791	0.000791	CcSEcCtD
Ramipril—Malaise—Methotrexate—lymphatic system cancer	0.000769	0.000769	CcSEcCtD
Ramipril—Vertigo—Methotrexate—lymphatic system cancer	0.000766	0.000766	CcSEcCtD
Ramipril—Leukopenia—Methotrexate—lymphatic system cancer	0.000763	0.000763	CcSEcCtD
Ramipril—Cough—Methotrexate—lymphatic system cancer	0.000744	0.000744	CcSEcCtD
Ramipril—Convulsion—Methotrexate—lymphatic system cancer	0.000738	0.000738	CcSEcCtD
Ramipril—Chest pain—Methotrexate—lymphatic system cancer	0.000726	0.000726	CcSEcCtD
Ramipril—Myalgia—Methotrexate—lymphatic system cancer	0.000726	0.000726	CcSEcCtD
Ramipril—Arthralgia—Methotrexate—lymphatic system cancer	0.000726	0.000726	CcSEcCtD
Ramipril—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Ramipril—Discomfort—Methotrexate—lymphatic system cancer	0.000717	0.000717	CcSEcCtD
Ramipril—Confusional state—Methotrexate—lymphatic system cancer	0.000701	0.000701	CcSEcCtD
Ramipril—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000696	0.000696	CcSEcCtD
Ramipril—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000682	0.000682	CcSEcCtD
Ramipril—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000681	0.000681	CcSEcCtD
Ramipril—Skin disorder—Methotrexate—lymphatic system cancer	0.000676	0.000676	CcSEcCtD
Ramipril—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000672	0.000672	CcSEcCtD
Ramipril—Anorexia—Methotrexate—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Ramipril—Hypotension—Methotrexate—lymphatic system cancer	0.00065	0.00065	CcSEcCtD
Ramipril—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000634	0.000634	CcSEcCtD
Ramipril—Insomnia—Methotrexate—lymphatic system cancer	0.000629	0.000629	CcSEcCtD
Ramipril—Paraesthesia—Methotrexate—lymphatic system cancer	0.000625	0.000625	CcSEcCtD
Ramipril—Dyspnoea—Methotrexate—lymphatic system cancer	0.00062	0.00062	CcSEcCtD
Ramipril—Somnolence—Methotrexate—lymphatic system cancer	0.000618	0.000618	CcSEcCtD
Ramipril—Dyspepsia—Methotrexate—lymphatic system cancer	0.000612	0.000612	CcSEcCtD
Ramipril—Decreased appetite—Methotrexate—lymphatic system cancer	0.000605	0.000605	CcSEcCtD
Ramipril—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000601	0.000601	CcSEcCtD
Ramipril—Fatigue—Methotrexate—lymphatic system cancer	0.0006	0.0006	CcSEcCtD
Ramipril—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000573	0.000573	CcSEcCtD
Ramipril—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000569	0.000569	CcSEcCtD
Ramipril—Urticaria—Methotrexate—lymphatic system cancer	0.000553	0.000553	CcSEcCtD
Ramipril—Abdominal pain—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Ramipril—Body temperature increased—Methotrexate—lymphatic system cancer	0.00055	0.00055	CcSEcCtD
Ramipril—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000512	0.000512	CcSEcCtD
Ramipril—Asthenia—Methotrexate—lymphatic system cancer	0.000499	0.000499	CcSEcCtD
Ramipril—Pruritus—Methotrexate—lymphatic system cancer	0.000492	0.000492	CcSEcCtD
Ramipril—Diarrhoea—Methotrexate—lymphatic system cancer	0.000476	0.000476	CcSEcCtD
Ramipril—Dizziness—Methotrexate—lymphatic system cancer	0.00046	0.00046	CcSEcCtD
Ramipril—Vomiting—Methotrexate—lymphatic system cancer	0.000442	0.000442	CcSEcCtD
Ramipril—Rash—Methotrexate—lymphatic system cancer	0.000439	0.000439	CcSEcCtD
Ramipril—Dermatitis—Methotrexate—lymphatic system cancer	0.000438	0.000438	CcSEcCtD
Ramipril—Headache—Methotrexate—lymphatic system cancer	0.000436	0.000436	CcSEcCtD
Ramipril—Nausea—Methotrexate—lymphatic system cancer	0.000413	0.000413	CcSEcCtD
